Conversely, in a murine model of medullary breast adenocarcinoma, intratumorally delivered 177Lu-BSA-tetrazine RPT significantly decreased CD8+ T cells in the TME; however, this decrease was not seen in the CD8+ T cells in the peripheral blood (95). The gene discussed is CD8A; the disease is breast adenocarcinoma.